Scientist I/II, Translational Medicine - Boston, United States - Elicio Therapeutics

Description

Job Description

Reporting to the Senior Scientist I of Translational Medicine, this individual will serve as an integral team member with exposure to multiple facets of business operations. The Scientist I will be responsible for conducting immunogenicity assays that measure vaccine efficacy, such as ELISpot/Fluorospot, ICS, and other flow cytometry-based assays. As part of the organization's Translational Medicine team, this individual will interact collaboratively with the Clinical Operations and Analytical Chemistry departments to successfully progress current and future clinical programs. Additional attributes of the position include responsibility for performing in vivo mouse experiments to characterize the immune response to vaccine candidates.

Elicio (ELTX) is a growing organization based out of the Seaport area of Boston, Massachusetts with additional staff functioning in a virtual-based environment from the Greater Boston area and throughout the United States.

This position does not allow for remote work and requires onsite attendance.

Major Duties/Responsibilities

• Perform, troubleshoot and analyze immunogenicity assays that measure vaccine efficacy, such as ELISPOT/Fluorospot, ICS, and other flow cytometry-based assays
• Execute stage-appropriate sample management, testing logistics, data analysis, and interpretation of clinical results
• Produce clinical data packets in collaboration with the QC department to ensure proper documentation of the methods as they are written
• Perform human specimen processing for PBMC under the guidelines of the ELI-002 clinical trial
• Develop and optimize immunogenicity assays to characterize immune responses to vaccines and implement novel technologies
• Design and execute in vivo murine experiments to evaluate vaccine immunogenicity
• Author and review SOPs and technical reports
• Contribute to the prioritization of projects and goals for the Translational Medicine team
• Manage and mentor members of the Translational Medicine team to support the timely completion of assay development and clinical testing within the lab
• Interact collaboratively with the clinical operations team and other key stakeholders to progress the clinical testing program
• Complete job responsibilities in compliance with GCLP guidelines, where applicable

Education & Professional Experience

Required:

• With 0-3 years, MS with 5+ years or BS with 10+ years of relevant work experience in an academic or industry environment.

Skills:

• Background in immunology
• Experience with T cell-based assays and multi-color flow cytometry-based assays
• Experience managing direct reports preferred but not necessary
• Whole blood processing for PBMC
• Murine handling techniques and injections
• Strong written and verbal communication skills suited for work in a matrixed environment of immunologists, analytical chemists, and clinicians
• Attention to detail and familiarity with GCLP guidelines
• Understanding of translational workflows and clinical trial design a plus

Working Conditions

Busy office/laboratory environment with frequent deadlines and interruptions

Travel: Travel is not required

Physical Requirements: Subject to periods of sitting or standing, vision is required to monitor data.

To Apply: Please submit your resume to using the job title in the email subject line.

About Elicio Therapeutics

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (AMP) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases. The AMP platform emerged from the laboratories of Darrell Irvine, Howard Hughes Investigator and Professor of Biomedical Engineering in the Koch Institute of Integrative Cancer Research at MIT. For more information, please visit

About the Amphiphile Platform

Elicio Therapeutics' proprietary Amphiphile ("AMP") platform delivers investigational immunotherapeutics directly to the "brain center" of the immune system – the lymph nodes. Elicio believes this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators may efficiently educate, activate, and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, Elicio has observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. Elicio believes our AMP lymph node-targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes based upon preclinical studies. Elicio's AMP platform, originally developed at the Massachusetts Institute of Technology has broad potential in the cancer space to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships. The AMP platform has been shown to deliver immunotherapeutics directly to the lymph nodes by latching on to the protein albumin, found in the bloodstream, as it travels to lymphatic tissue. In preclinical models, Elicio has observed lymph node-specific engagement driving immune responses of increased magnitude, function and durability.